Role of <i>CYP2D6</i> Gene Variants and Family History in Personalized Antidepressant Treatments for Depression

Depression is a globally prevalent mental health disorder characterized by significant variability in the treatment responses owing to genetic, environmental, and familial factors. Current antidepressant therapies, primarily targeting the neurotransmitter balance, often fail to achieve consistent efficacy across all patients and may have severe side effects in a significant minority. This underscores the critical need for personalized treatment approaches. Pharmacogenomics is a pivotal tool in precision medicine, particularly by analyzing the CYP2D6 gene, which plays a key role in metabolizing various antidepressants. Variations in CYP2D6 can classify individuals into different metabolizer types, directly influencing drug efficacy and the risk of adverse reactions. Integrating pharmacogenomic data with family history offers a comprehensive strategy to optimize antidepressant therapy, enhancing clinical outcomes and reducing healthcare costs. On the other hand, the clinical implementation of pharmacogenomics faces challenges, such as limited genetic data for diverse populations, high costs of genetic testing, lack of standardized protocols, and ethical concerns regarding genetic information privacy. Overcoming these barriers through collaborative research, policy development, and healthcare professional education is essential for the widespread adoption of pharmacogenomics in depression treatment. Ultimately, personalized medicine based on pharmacogenomic insights has the potential to improve the effectiveness and safety of depression therapies.